» Authors » Ana Maria Gimenez-Arnau

Ana Maria Gimenez-Arnau

Explore the profile of Ana Maria Gimenez-Arnau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 51
Citations 122
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Pesque D, Silvestre-Salvador J, Figueiredo A, Pujol R, Goncalo M, Gimenez-Arnau A
Contact Dermatitis . 2025 Feb; PMID: 39994885
Hand eczema is a common dermatological condition that significantly impairs quality of life. The classification of hand eczema has been considered an essential step for its management. The diagnosis of...
2.
Gimenez-Arnau A, Balp M, Danyliv A, Winders T, ODonoghue J, Kleebach J, et al.
Patient . 2025 Jan; 18(2):173-185. PMID: 39873902
Background: In the context of injectable biologic products approved or in development for chronic spontaneous urticaria (CSU), it is important to capture which treatment attributes matter most to patient and...
3.
Apfelbacher C, Bewley A, Molin S, Fargnoli M, Gimenez-Arnau A, Brignoli L, et al.
Br J Dermatol . 2025 Jan; PMID: 39797908
Background: The lack of attention to Chronic Hand Eczema (CHE) and the lack of a specific International Classification of Diseases code for CHE may have limited the assessment of CHE...
4.
Wilkinson S, Aerts O, Agner T, Bruze M, Brans R, Foti C, et al.
Contact Dermatitis . 2024 Dec; 92(4):283-290. PMID: 39721608
Background: There is a current fashion for the use of methacrylate-containing nail cosmetics that can induce allergic contact dermatitis. European Union (EU) legislation was introduced in 2021 that had the...
5.
Podder I, Salman A, Asero R, Teresa Caballero M, Caffarelli C, De Las Vecillas L, et al.
Expert Rev Clin Immunol . 2024 Nov; 20(12):1427-1435. PMID: 39555837
Introduction: There is a significant prevalence of chronic spontaneous urticaria (CSU) in children across the globe. Some children with CSU do not achieve disease control with first-line antihistamine treatment and...
6.
Pesque D, Planella-Fontanillas N, Borrego L, Sanz-Sanchez T, Zaragoza-Ninet V, Serra-Baldrich E, et al.
Contact Dermatitis . 2024 Oct; 92(2):120-130. PMID: 39394969
Introduction: Patch test results may be influenced by age-related factors. However, there is still discordant evidence between age and patch test results. Objectives: We aim to evaluate the patch test...
7.
Gatica-Ortega M, Pastor-Nieto M, Gimenez-Arnau A, Mercader-Garcia P, Serra-Baldrich E, Zaragoza-Ninet V, et al.
Contact Dermatitis . 2024 Aug; 91(5):379-386. PMID: 39164011
Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione. Objective: To evaluate a...
8.
Schwensen J, Uter W, Aerts O, Agner T, Brans R, Bruze M, et al.
Contact Dermatitis . 2024 Jul; 91(4):271-277. PMID: 39021255
Background: The use of methylisothiazolinone (MI) as a preservative in cosmetic products caused an alarming increase in MI contact allergy across Europe in the 2010s. This was followed by regulations...
9.
Mercader-Garcia P, Silvestre J, Navarro-Trivino F, Gimenez-Arnau A, Pastor-Nieto M, Cordoba-Guijarro S, et al.
Contact Dermatitis . 2024 Jul; 91(3):228-236. PMID: 38965446
Background: Budesonide and tixocortol pivalate as markers of contact allergy to corticosteroids have been questioned, as they are not able to detect a significant percentage of allergic patients. Objectives: To...
10.
John S, Bonertz A, Zimmer J, Aerts O, Bauer A, Bova M, et al.
Contact Dermatitis . 2024 May; 91(2):91-103. PMID: 38812248
Patch testing is the only clinically applicable diagnostic method for Type IV allergy. The availability of Type IV patch test (PT) allergens in Europe, however, is currently scarce. This severely...